Kai Li

机构：Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Digestive Diseases, People's Hospital of Xinjiang Uygur Autonomous Region, Second Affiliated Hospital of Nanjing Medical University, Baotou Medical College, China Medical University · ORCID：0000-0002-6895-0024

发表论文 139 篇 · 总被引 3659 次 · h-index 31

代表论文

• Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant (2024 · JAMA · 被引 187)
• Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC (2025 · New England Journal of Medicine · 被引 61)
• The adhesion-GPCR ADGRF5 fuels breast cancer progression by suppressing the MMP8-mediated antitumorigenic effects (2024 · Cell Death and Disease · 被引 19)
• Immune‐independent acquired resistance to PD‐L1 antibody initiated by PD‐L1 upregulation via PI3K / AKT signaling can be reversed by anlotinib (2023 · Cancer Medicine · 被引 16)
• Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial. (2024 · Journal of Clinical Oncology · 被引 14)
• Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study☆ (2024 · JHEP Reports · 被引 11)